{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:00:59Z","timestamp":1784948459726,"version":"3.55.0"},"reference-count":43,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy derived from plasmacytoid dendritic cells. It commonly presents as cutaneous lesions. To date, no standard treatment protocol for BPDCN exists. Traditionally treated similarly to acute leukemia or lymphoma, its prognosis remains poor. Radiation therapy is employed for isolated skin lesions, for patients that are ineligible for chemotherapy due to age or comorbidities and for post-chemotherapy recurrence. However, very limited reports are available on radiotherapy for BPDCN. We present a case involving a 94-year-old BPDCN patient treated with radiation therapy, highlighting an atypical situation of two separate radiotherapy sessions with different dosages for isolated skin lesions. Initially, 45 Gy was administered in 15 fractions (45 Gy\/15 Fr), followed by a second session of 30 Gy in 10 fractions (30 Gy\/10 Fr) after disease recurrence. This case is unique in detailing radiation therapy for the exceedingly rare BPDCN, particularly dose fractionation. The findings indicate that 45 Gy\/15 Fr can provide adequate local control, while even a lower dose of 30 Gy\/10 Fr may be effective. This case report contributes to the limited literature by proposing potential therapeutic approaches and dosage guidelines to refine future BPDCN treatment protocols.<\/jats:p>","DOI":"10.3390\/curroncol31110524","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T08:09:28Z","timestamp":1731485368000},"page":"7117-7128","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radiation Therapy for Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report and Review of the Literature"],"prefix":"10.3390","volume":"31","author":[{"given":"Masashi","family":"Taka","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Toyama Prefectural Central Hospital, 2-2-78, Nishinagae, Toyama City 930-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Toyoshima","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Toyama Prefectural Central Hospital, 2-2-78, Nishinagae, Toyama City 930-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0743-4413","authenticated-orcid":false,"given":"Shigeyuki","family":"Takamatsu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Graduate School of Medical Sciences, Kanazawa University, 13-1, Takara-machi, Kanazawa City 920-8641, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7759-399X","authenticated-orcid":false,"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Graduate School of Medical Sciences, Kanazawa University, 13-1, Takara-machi, Kanazawa City 920-8641, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"ref_1","unstructured":"Facchetti, F., Ungari, M., Marocolo, D., Lonardi, S., and Vermi, W. (2009, January 26\u201329). Blastic plasmacytoid dendritic cell neoplasm. Proceedings of the7th Meeting New Insights in Hematology, Venice, Italy."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1182\/blood.V99.5.1556","article-title":"Clinical and biologic features of CD4(+)CD56(+) malignancies","volume":"99","author":"Feuillard","year":"2002","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bjd.12412","article-title":"Blastic plasmacytoid dendritic cell neoplasm: Clinical features in 90 patients","volume":"169","author":"Julia","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/1097-0142(19950515)75:10<2474::AID-CNCR2820751013>3.0.CO;2-Y","article-title":"Acute agranular CD4-positive natural killer cell leukemia. Comprehensive clinicopathologic studies including virologic and in vitro culture with inducing agents","volume":"75","author":"Brody","year":"1995","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_8","first-page":"58","article-title":"Incidence and characteristics of CD4(+)\/HLA DRhi dendritic cell malignancies","volume":"89","author":"Bueno","year":"2004","journal-title":"Haematologica"},{"key":"ref_9","first-page":"8204","article-title":"Radiation therapy for cutaneous blastic plasmacytoid dendritic cell neoplasm: A case report and review of the literature","volume":"8","author":"Ishibashi","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1309\/GJWNPD8HU5MAJ837","article-title":"Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): A review","volume":"123","author":"Petrella","year":"2005","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: An Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1182\/blood.V97.10.3210","article-title":"Identification of a leukemic counterpart of the plasmacytoid dendritic cells","volume":"97","author":"Chaperot","year":"2001","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood-2007-10-117531","article-title":"Novel markers of normal and neoplastic human plasmacytoid dendritic cells","volume":"111","author":"Marafioti","year":"2008","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/leu.2014.64","article-title":"Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition","volume":"28","author":"Sapienza","year":"2014","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-023-06156-8","article-title":"Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin","volume":"618","author":"Griffin","year":"2023","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/s41375-022-01538-9","article-title":"Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients","volume":"36","author":"Khanlari","year":"2022","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-20-1513","article-title":"Sex-Biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis","volume":"12","author":"Togami","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ccell.2016.10.002","article-title":"A druggable TCF4\u2212 and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm","volume":"30","author":"Ceribelli","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2006-04-018143","article-title":"Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities","volume":"109","author":"Dijkman","year":"2007","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.leukres.2011.07.033","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review","volume":"36","author":"Rauh","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10174","DOI":"10.18632\/oncotarget.7101","article-title":"Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy","volume":"7","author":"Almeida","year":"2016","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_24","first-page":"173","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","volume":"Volume 4","author":"Swerdlow","year":"2017","journal-title":"WHO Classification of Tumours"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cyto.a.22628","article-title":"Single-cell mass cytometry reveals intracellular survival\/proliferative signaling in FLT3-ITD-mutated AML stem\/progenitor cells","volume":"87","author":"Han","year":"2015","journal-title":"Cytom. Part. A"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., and Frankel, A. (2014). CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark. Res., 2.","DOI":"10.1186\/2050-7771-2-4"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/MPH.0000000000000964","article-title":"Pediatric blastic plasmacytoid dendritic cell neoplasm: A systematic literature review","volume":"39","author":"Kim","year":"2017","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.bmt.1704215","article-title":"What is CD4+CD56+ malignancy and how should it be treated?","volume":"32","author":"Reimer","year":"2003","journal-title":"Bone Marrow Transpl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2019001144","article-title":"Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark","volume":"134","author":"Taylor","year":"2019","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.leukres.2018.01.013","article-title":"8q24\/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms","volume":"66","author":"Boddu","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1038\/s41375-018-0154-5","article-title":"Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: Association with immunoblastoid cytomorphology, MYC expression, and drug response","volume":"32","author":"Sakamoto","year":"2018","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/his.13668","article-title":"An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality","volume":"73","author":"Lezama","year":"2018","journal-title":"Histopathology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.critrevonc.2016.09.003","article-title":"A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm","volume":"107","author":"Falcone","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.2147\/OTT.S250016","article-title":"Case report of anti-CD123 chimeric antigen receptor T-cell therapy followed by radiotherapy for a recurrence of blastic plasmacytoid dendritic cell neoplasm after allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Jiang","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/j.1365-2230.2008.03100.x","article-title":"Haematodermic CD4+CD56+ neoplasm: Complete remission after methotrexate-asparaginase treatment","volume":"34","author":"Fontaine","year":"2009","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3960\/jslrt.52.23","article-title":"Blastic plasmacytoid dendritic cell neoplasm: Report of two cases","volume":"52","author":"Tsunoda","year":"2012","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jdcr.2017.03.015","article-title":"Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation","volume":"3","author":"Sundram","year":"2017","journal-title":"JAAD Case Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/DAD.0b013e3181a5e13d","article-title":"Solitary cutaneous nodule of blastic plasmacytoid dendritic cell neoplasm progressing to overt leukemia cutis after chemotherapy: Immunohistology and FISH analysis confirmed the diagnosis","volume":"31","author":"Kaune","year":"2009","journal-title":"Am. J. Dermatopathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/bmt.2010.196","article-title":"Progression of a CD4+\/CD56+ blastic plasmacytoid DC neoplasm after initiation of extracorporeal photopheresis in an allogeneic transplant recipient","volume":"46","author":"Dohm","year":"2011","journal-title":"Bone Marrow Transpl."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00277-014-2193-y","article-title":"Sustained remission of blastic plasmacytoid dendritic cell neoplasm after unrelated allogeneic stem cell transplantation\u2014A single center experience","volume":"94","author":"Heinicke","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3892\/ol.2014.2759","article-title":"Blastic plasmacytoid dendritic cell neoplasm presenting with a cutaneous tumor alone as the first symptom of onset: A case report and review of literature","volume":"9","author":"Yu","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3960\/jslrt.51.49","article-title":"Bilateral conjunctival lesions in blastic plasmacytoid dendritic cell neoplasm","volume":"51","author":"Matsuo","year":"2011","journal-title":"J. Clin. Exp. Hematop."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/11\/524\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:31:30Z","timestamp":1760113890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/11\/524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["curroncol31110524"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31110524","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]}}}